An FDA advisory panel gave its unanimous backing to the second in what is likely to be a lengthening line of premarket approval (PMAs) applications for drug-eluting stents (DES). The nod went to the Taxus paclitaxel-eluting coronary stent from Boston Scientific (Natick, Massachusetts).
Browse by Speciality Area